Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

4.88$0.05 1.04%
At close       04:00 PM   

Stock Snapshot

4.83
Prev. Close
4.82
Open
132.64M
Market Cap
119250.00
Number of Shares
4.7000
Day Low
4.8800
Day High
4.88
-
P/E Ratio
18.11M
Free Float in %
-0.89
EPS 2021
1.08
Book Value per Share
0.99
Cash Flow per Share
Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX) stock rallied over 1.04% intraday to trade at $4.88 share on NASDAQ. The stock opened with a fall of % at $4.82 and touched an intraday high of $4.8800, rising 1.04% against the last close of $4.83. The stock went to a low of $4.7000 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$4.67$4.70$4.78$4.63113,503
2021-09-03$5.00$5.09$5.17$5.0012,510,000
2021-09-02$5.20$5.04$5.39$4.8533,720,000
2021-09-01$4.92$5.16$5.18$4.8815,090,000
2021-08-31$4.86$4.88$4.90$4.814,900,000
2021-08-30$4.70$4.82$4.92$4.707,480,000
2021-08-27$4.90$4.84$4.99$4.797,780,000
2021-08-26$5.00$4.86$5.07$4.828,910,000
2021-08-25$5.05$5.02$5.18$4.9019,670,000
2021-08-24$4.75$5.06$5.07$4.7515,020,000
2021-08-23$4.57$4.75$4.76$4.5013,020,000
Entera Bio Ltd.
Minrav Building
Fifth Floor Kiryat Hadassah PO Box 12117
Jerusalem 9112002
Israel

http://www.enterabio.com
972 2 532 7151
Employees
19
Sector
Healthcare
Sales or Revenue
500000.00
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam